Why Is Zoetis (ZTS) Stock Down -13% Today?
Key Takeaways
- ZTS shares plunged approximately 13.81% in premarket trading on May 7, 2026, falling from a prior close of $111.22 to around $95.86
- The primary catalyst was a disappointing Q1 2026 earnings report released before the market open, with both revenue and adjusted EPS missing Wall Street consensus estimates
- Revenue came in at $2.26 billion, a 2.1% miss versus analyst expectations of $2.31 billion, while adjusted EPS of $1.53 fell 5.3% short of the $1.62 consensus
- Adjusted EBITDA missed estimates by a striking 24.6%, reflecting a sharp decline in operating margin from 38.1% to 33.5% year-over-year
- The company cut its full-year 2026 guidance, lowering the revenue midpoint to $9.82 billion and adjusted EPS guidance to $6.93 at the midpoint — both below prior forecasts
- Traders are now focused on the earnings conference call at 8:30 AM ET and any management commentary on U.S. competitive pressures, Librela recovery, and tariff headwinds
Opening Summary
Zoetis Inc. (ZTS) is the world's leading animal health company, focused on the discovery, development, and commercialization of medicines, vaccines, and diagnostic products for both companion animals and livestock. Shares are trading down approximately 13.81% in premarket on May 7, 2026, after the company reported its Q1 2026 results before the open. The prior session's closing price was $111.22, with premarket levels around $95.86, reflecting a significant earnings-driven sell-off. The decline was triggered by a broad miss across revenue, earnings, and profitability metrics, compounded by a downward revision to full-year guidance.
Earnings Miss Across the Board
Zoetis posted Q1 2026 revenue of $2.26 billion, growing just 1.9% year-over-year and missing the $2.31 billion analyst consensus by 2.1%. Adjusted EPS of $1.53 fell well short of the expected $1.62, representing a 5.3% miss. Most strikingly, adjusted EBITDA came in at $789 million versus the $1.05 billion estimate — a 24.6% shortfall — while operating margin contracted sharply to 33.5% from 38.1% in Q1 2025. The depth of the margin deterioration caught analysts and investors off guard.
U.S. Segment Weakness and Competitive Pressure
The U.S. segment was the primary drag, with domestic revenue falling 8% year-over-year. Companion animal product sales dropped 11%, hurt by softer end-market demand, macroeconomic-driven price sensitivity, and intensifying competition. The dermatology franchise and Simparica Trio faced heightened rivalry, while generic competition weighed on Convenia and Cerenia revenues. Sales of Librela — Zoetis's monoclonal antibody treatment for canine osteoarthritis pain — also declined, continuing a trend of muted adoption linked to lingering side-effect perceptions that has dogged the product for several quarters.
Guidance Cut Amplifies Concerns
Beyond the headline miss, Zoetis revised its full-year 2026 revenue guidance downward to a range of $9.68 billion to $9.96 billion, with a midpoint of $9.82 billion — roughly 1.1% below the prior $9.93 billion midpoint. Full-year adjusted EPS guidance was cut to $6.85–$7.00, compared to the previous range of $7.00–$7.10. The revised organic revenue growth outlook of 2%–5% fell below the 3%–5% target management had communicated entering the year. Investors interpreted the guidance reduction as a signal that competitive and macroeconomic headwinds are proving more persistent than expected.
Macro and Tariff Headwinds
Broader macro conditions have been a recurring theme for ZTS in recent quarters. Pet owners have been demonstrating heightened price sensitivity, leading to fewer elective veterinary visits and reduced spending on premium animal health products. Additionally, tariff exposure — particularly on active pharmaceutical ingredients (APIs) imported from China used in certain livestock products and diagnostics — has added cost pressure that management has been working to mitigate. These macro forces compounded the already-stiff competitive dynamics facing ZTS's core U.S. product lines.
Market Context and Trading Activity
The sell-off in ZTS is notably outsized relative to the broader market and sector. The stock had already been under pressure, trading near 52-week lows ahead of today's report, with shares having shed roughly 29% over the past year. The premarket volume is elevated, consistent with a major post-earnings reaction. While the international segment offered a partial offset — growing 17% on a reported basis aided by fiscal year alignment — it was insufficient to counterbalance the U.S. deterioration or sway investor sentiment. The animal health sector, including peers like Elanco Animal Health (ELAN), will likely face sympathy pressure as the market opens.
Trending AI Robots
For traders looking to navigate volatility like today's ZTS move, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI bots covering thousands of tickers, spanning a wide variety of strategies, timeframes, performance metrics, and traded symbols — but only those demonstrating the strongest real-time performance are featured in the Trending section. Whether you prefer momentum strategies, mean-reversion approaches, or sector-specific plays, the Trending AI Robots section provides a focused starting point for identifying bots that are working right now. Explore the page to find a bot strategy that aligns with your risk tolerance and investment objectives.
What Comes Next for ZTS
The immediate focus is on Zoetis's earnings conference call at 8:30 AM ET on May 7, where management will likely address the trajectory of Librela in the U.S., competitive dynamics in dermatology, and specific tariff mitigation strategies for the remainder of 2026. Analysts will be scrutinizing whether the guidance cut appropriately absorbs ongoing headwinds or if further reductions remain possible. A new product pipeline — including innovations in oncology and cardiology for companion animals — is expected to become a more meaningful revenue contributor starting in 2027, but near-term catalysts remain limited. The consensus analyst rating on ZTS was already a mixed "Hold" with a price target of $151.75 ahead of today's report, and target reductions are likely to follow. Risks include continued erosion in U.S. companion animal spending, further Librela adoption challenges, and the uncertain impact of evolving tariff policy on input costs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ZTS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ZTS turned positive on August 19, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on August 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
ZTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 206 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on August 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZTS as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ZTS moved below its 50-day moving average on August 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.152) is normal, around the industry mean (47.174). P/E Ratio (12.617) is within average values for comparable stocks, (94.151). ZTS's Projected Growth (PEG Ratio) (6.930) is very high in comparison to the industry average of (2.206). Dividend Yield (0.027) settles around the average of (0.029) among similar stocks. P/S Ratio (3.495) is also within normal values, averaging (177.105).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a pet medication company
Industry PharmaceuticalsGeneric
Advertisement